Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults
NCT06665555Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ledaborbactam etzadroxil in bacterial infection (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Intrapulmonary Pharmacokinetics - Area Under the Curve From Time Zero to 12 Hours at Steady State, Plasma Maximum Concentration of Ceftibuten at 12 hours and 5 more. Started Nov 2024; status: completed.
02
Drugs
ledaborbactam etzadroxil
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06665555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665555.